User:Elizabeth Perkins: Difference between revisions
| Line 103: | Line 103: | ||
Bradley Olwin, PhD | Bradley Olwin, PhD | ||
"The Role of the Niche in Self-Renewal & Transplantation of Muscle Stem Cells" | "The Role of the Niche in Self-Renewal & Transplantation of Muscle Stem Cells" | ||
http://www.ohsu.edu/edcomm/flash/flash_player.php?params=4%60/res/kci/seminar121311.flv%60vod&width=640&height=480&title=Knight%20Cancer%20Institute%20Seminar%20December%2013th%2C%202011 | http://www.ohsu.edu/edcomm/flash/flash_player.php?params=4%60/res/kci/seminar121311.flv%60vod&width=640&height=480&title=Knight%20Cancer%20Institute%20Seminar%20December%2013th%2C%202011 | ||
| Line 109: | Line 110: | ||
Alexander Gimelbrant, PhD | Alexander Gimelbrant, PhD | ||
"Autosomal Analog of X-Inactivation" | "Autosomal Analog of X-Inactivation" | ||
http://www.ohsu.edu/edcomm/flash/flash_player.php?params=1%60/res/kci/seminar111511.flv%60vod%60s&width=640&height=480&sec=true&title=Knight%20Cancer%20Institute%20Seminar%20Series%2C%2011/15/11 | http://www.ohsu.edu/edcomm/flash/flash_player.php?params=1%60/res/kci/seminar111511.flv%60vod%60s&width=640&height=480&sec=true&title=Knight%20Cancer%20Institute%20Seminar%20Series%2C%2011/15/11 | ||
| Line 115: | Line 117: | ||
Ranadip Pal, PhD | Ranadip Pal, PhD | ||
“Modeling Cancer Pathways: How Mathematical Modeling can Assist in Selecting & Predicting the Effectiveness of Targeted Drug Combinations” | “Modeling Cancer Pathways: How Mathematical Modeling can Assist in Selecting & Predicting the Effectiveness of Targeted Drug Combinations” | ||
http://www.ohsu.edu/edcomm/flash/flash_player.php?params=4%60/res/kci/seminar101811.flv%60vod%60s&width=640&height=480&sec=true&title=Knight%20Cancer%20Institute%20Seminar%20Series%2C%20Oct.%2018%2C%202011 | http://www.ohsu.edu/edcomm/flash/flash_player.php?params=4%60/res/kci/seminar101811.flv%60vod%60s&width=640&height=480&sec=true&title=Knight%20Cancer%20Institute%20Seminar%20Series%2C%20Oct.%2018%2C%202011 | ||
| Line 121: | Line 124: | ||
Paul T. Spellman, PhD | Paul T. Spellman, PhD | ||
“Systems Approaches to Understanding Cancer Biology & Treatment” | “Systems Approaches to Understanding Cancer Biology & Treatment” | ||
http://www.ohsu.edu/edcomm/flash/flash_player.php?params=4%60/res/kci/seminar100411.flv%60vod%60s&width=640&height=480&sec=true&title=Knight%20Cancer%20Institute%20Seminar%20Series%2C%20Oct.%204%2C%202011 | http://www.ohsu.edu/edcomm/flash/flash_player.php?params=4%60/res/kci/seminar100411.flv%60vod%60s&width=640&height=480&sec=true&title=Knight%20Cancer%20Institute%20Seminar%20Series%2C%20Oct.%204%2C%202011 | ||
| Line 127: | Line 131: | ||
William Stratford May, MD, PhD | William Stratford May, MD, PhD | ||
“TNK1/KOS1: A Protein Tyrosine Kinase with a Tumor Suppressor Function” | “TNK1/KOS1: A Protein Tyrosine Kinase with a Tumor Suppressor Function” | ||
http://www.ohsu.edu/edcomm/flash/flash_player.php?params=4%60/res/kci/may062111.flv%60vod%60s&width=640&height=480&sec=true&title=Knight%20Cancer%20Institute%20Seminar%2C%20June%2021.%202011 | http://www.ohsu.edu/edcomm/flash/flash_player.php?params=4%60/res/kci/may062111.flv%60vod%60s&width=640&height=480&sec=true&title=Knight%20Cancer%20Institute%20Seminar%2C%20June%2021.%202011 | ||
| Line 133: | Line 138: | ||
James Ford, MD | James Ford, MD | ||
“Targeting DNA Repair for the Treatment and Prevention of Triple-Negative Breast Cancer” | “Targeting DNA Repair for the Treatment and Prevention of Triple-Negative Breast Cancer” | ||
http://www.ohsu.edu/edcomm/flash/flash_player.php?params=4%60/res/kci/ford061411.flv%60vod%60s&width=640&height=480&sec=true&title=Knight%20Cancer%20Institute%20Seminar%20Series%2C%20June%2014%2C%202011 | http://www.ohsu.edu/edcomm/flash/flash_player.php?params=4%60/res/kci/ford061411.flv%60vod%60s&width=640&height=480&sec=true&title=Knight%20Cancer%20Institute%20Seminar%20Series%2C%20June%2014%2C%202011 | ||
Latest revision as of 14:41, 21 December 2011
Knight Cancer Institute Seminar Series
- Jodi Collier, Event Coordinator
- OHSU Knight Cancer Institute
- 3181 SW Sam Jackson Park Road
- Portland, OR 97239
- 503-494-8673
- collier@ohsu.edu
http://portal.ohsu.edu/blogs/researchnews/
Objectives of the Knight Cancer Institute Seminar Series
The 2nd Annual Knight Cancer Institute Seminar series, co-sponsored by the Pediatric Cancer Biology program and the Knight Cancer Institute, will have a strong presence of childhood cancer basic and translational research topics presented by leading extramural scientists.
4:00pm TUESDAYS - OHSU MAIN HOSPITAL 8TH FLOOR CONFERENCE ROOM 8B60
-Schedule Subject to Chage-
October 4, 2011
Paul T. Spellman, PhD - OHSU
October 18, 2011
Ranadip Pal, PhD - Texas Tech
November 15, 2011
Alexander A. Gimelbrant, PhD - Dana Farber Cancer Institute
December 13, 2011
Bradley Bruce Olwin, PhD - Colorado University - Boulder
January 15, 2012
Robin Jones, Bsc, MB, MRCP, MD (Res) / Seth Pollack, MD - University of Washington - Seattle Cancer Care Alliance
January 31, 2012
Mark Kieran, MD, PhD - Dana Farber Cancer Institute
February 21, 2012
Doug Yee, MD - Masonic Center University of Minnesota
February 28, 2012
Gordon B. Mills, MD, PhD - MD Anderson Cancer Center
March 13, 2012
Jeffrey M. Rosen, PhD - Baylor College of Medicine
March 20, 2012
Wei Xu, PhD - University of Wisconsin-Madison
March 27, 2012
Massimo Loda, MD - Dana-Farber Cancer Institute
April 17, 2012 - Location Changed to CHH 3171 1a / 3181 1b
Elizabeth Blackburn, PhD - University of California San Francisco
April 24, 2012
Thomas A. Rando, MD, PhD - Stanford University School of Medicine
May 8, 2012
David M. Langenau, PhD - Massachusetts General Hospital
June 5, 2012
Stephano Cairo, PhD - Xentech
October 23, 2012
Jeffrey Toretsky, PhD
Lombardi Comprehensive Cancer Center - Georgetown University
Links to Archived Seminars:
December 13, 2011 Bradley Olwin, PhD "The Role of the Niche in Self-Renewal & Transplantation of Muscle Stem Cells"
November 15, 2011
Alexander Gimelbrant, PhD
"Autosomal Analog of X-Inactivation"
October 18, 2011
Ranadip Pal, PhD
“Modeling Cancer Pathways: How Mathematical Modeling can Assist in Selecting & Predicting the Effectiveness of Targeted Drug Combinations”
October 4, 2011
Paul T. Spellman, PhD
“Systems Approaches to Understanding Cancer Biology & Treatment”
June 21, 2011
William Stratford May, MD, PhD
“TNK1/KOS1: A Protein Tyrosine Kinase with a Tumor Suppressor Function”
June 14, 2011
James Ford, MD
“Targeting DNA Repair for the Treatment and Prevention of Triple-Negative Breast Cancer”
